BioSpace News Archive

4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that the first patient has been dosed in the Phase 1/2 clinical trial of 4D-150 for neovascular age-related macular degeneration (wet AMD).

DURECT Corporation announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. Norman Sussman, Chief Medical Officer will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022.

Personalis, Inc., a leader in advanced genomics for cancer and population sequencing, reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2021.

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced the availability of MyoPro 2+, an enhanced version of its popular MyoPro powered brace.

WishBone Medical, Inc. and SpineGuard, an innovative company that deploys its Dynamic Surgical Guidance sensing technology to secure and streamline the placement of bone implants announced a long-term collaborative partnership with, for exclusive distribution rights of PediGuard® smart spinal drilling devices to children’s hospitals across the United States.

Johnson & Johnson (NYSE: JNJ) (the Company) today announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States (U.S.), showing that a single shot of the Johnson & Johnson COVID-19 vaccine resulted in long-lasting protection for up to six months against COVID-19 breakthrough infections, hospitalizations, and intensive care unit (ICU) admissions.

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2021 financial results on Thursday, February 17, 2022 at 7:30 a.m. Central Time.

QIAGEN N.V. announced important expansion initiatives for its QuantiFERON franchise, building on its status as the gold standard for detection of tuberculosis, while developing new applications for this technology designed to detect potentially deadly latent diseases.

n-Lorem, a nonprofit foundation, today noted important new guidance recently issued by the U.S. Food and Drug Administration (FDA) regarding both the manufacturing processes and stability testing required for antisense oligonucleotides (ASOs) to be administered to nano-rare patients and the clinical administration of ASO therapeutics for nano-rare patients.

Orca Bio, a clinical-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, today announced that Ivan Dimov, Ph.D., Orca Bio’s chief executive officer and co-founder, will present at the 40th Annual J.P. Morgan Healthcare Conference.